Home › Research › Disease mechanisms
Associations of KLOTHO-VS heterozygosity and α-Klotho protein with cerebrospinal fluid Alzheimer's disease biomarkers
Alžběta Katonová, Ross Andel, Vanesa Jurasova, Kateřina Veverová, Francesco Angelucci, Václav Maťoška, Jakub Hort. Journal of Alzheimer s Disease, 2025-03-20
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background KLOTHO -VS heterozygosity ( KL -VSHET) and soluble α-Klotho (sαKl) protein interfere with Alzheimer's disease (AD) pathophysiology, but the specific relationships remain unclear. This study explored these associations across the AD continuum, focusing on core AD biomarkers and markers of neurodegeneration, neuroinflammation, and synaptic dysfunction. Objective We investigated whether 1) KL -VSHET is associated with lower AD biomarker burden (Aβ 42 , Aβ 42/40 ratio, P-tau181, T-tau) and neurodegeneration (NfL); 2) sαKl relates to AD biomarkers, neurodegeneration (NfL), neuroinflammation (GFAP), and synaptic dysfunction (Ng); 3) associations vary by APOE ε4 status and clinical subgroup. Methods Participants (n = 223) were categorized as cognitively healthy (n = 38), aMCI-AD (n = 94), and AD dementia (n = 91). KLOTHO genotyping was available for 128 participants; 138 had cerebrospinal fluid (CSF) and serum sαKl measurements; and 42 had both. Multiple linear regression evaluated associations between KL -VSHET, sαKl levels, and biomarkers, stratified by APOE ε4 status and clinical subgroup. Results Overall, the associations between KL -VSHET and higher CSF Aβ 42 and Aβ 42/40 ratio were non-significant ( p s ≥ 0.059) except when restricted to APOE ε4 carriers only (β = 0.11, p = 0.008 and β = 0.16, p = 0.033, respectively). Within clinical subgroups, KL -VSHET was positively associated with Aβ 42/40 ratio only in aMCI-AD (β = 0.23, p = 0.034). No significant associations were observed between KL -VSHET and tau biomarkers or NfL. For sαKl, associations with biomarkers were non-significant except for a negative association of serum sαKl with P-tau181 in aMCI-AD (β = −0.25, p = 0.036) and a positive association with Aβ 42/40 ratio in APOE ε4 non-carriers (β = 0.24 p = 0.047). Conclusions KL -VSHET may help protect against amyloid pathology, particularly in the presence of APOE ε4, and regardless of APOE status in aMCI-AD.
What this study adds
Evidence grade: Low
The record lists 223 participants. In 223 participants across the Alzheimer's continuum, associations between KLOTHO-VS heterozygosity and higher cerebrospinal fluid Aβ42 and Aβ42/40 ratio were non-significant overall, except when restricted to APOE ε4 carriers. This is observational biomarker research and does not show that KLOTHO-VS heterozygosity or α-Klotho protein treats or prevents Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Katonová, A., Andel, R., Jurasova, V., Veverová, K., Angelucci, F., Maťoška, V., et al. (2025). Associations of KLOTHO-VS heterozygosity and α-Klotho protein with cerebrospinal fluid Alzheimer's disease biomarkers. Journal of Alzheimer s Disease. https://doi.org/10.1177/13872877251326199
Vancouver
Katonová A, Andel R, Jurasova V, Veverová K, Angelucci F, Maťoška V, et al. Associations of KLOTHO-VS heterozygosity and α-Klotho protein with cerebrospinal fluid Alzheimer's disease biomarkers. Journal of Alzheimer s Disease. 2025. doi:10.1177/13872877251326199. PMID: 40112321.
BibTeX
@article{katonova2025-40112321,
author = {Katonová, Alžběta and Andel, Ross and Jurasova, Vanesa and Veverová, Kateřina and Angelucci, Francesco and Maťoška, Václav and Hort, Jakub},
title = {{Associations of KLOTHO-VS heterozygosity and α-Klotho protein with cerebrospinal fluid Alzheimer's disease biomarkers}},
journal = {Journal of Alzheimer s Disease},
year = {2025},
doi = {10.1177/13872877251326199},
pmid = {40112321},
url = {https://doi.org/10.1177/13872877251326199}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Objective We investigated whether 1) KL -VSHET is associated with lower AD biomarker burden (Aβ 42 , Aβ 42/40 ratio, P-tau181, T-tau) and neurodegeneration (NfL); 2) sαKl relates to AD biomarkers, neurodegeneration (NfL), neuroinflammation (GFAP), and synaptic dysfunction (Ng); 3) associations vary by APOE ε4 status and clinical subgroup.
- Results Overall, the associations between KL -VSHET and higher CSF Aβ 42 and Aβ 42/40 ratio were non-significant ( p s ≥ 0.059) except when restricted to APOE ε4 carriers only (β = 0.11, p = 0.008 and β = 0.16, p = 0.033, respectively).
- Within clinical subgroups, KL -VSHET was positively associated with Aβ 42/40 ratio only in aMCI-AD (β = 0.23, p = 0.034).
- No significant associations were observed between KL -VSHET and tau biomarkers or NfL.
- For sαKl, associations with biomarkers were non-significant except for a negative association of serum sαKl with P-tau181 in aMCI-AD (β = −0.25, p = 0.036) and a positive association with Aβ 42/40 ratio in APOE ε4 non-carriers (β = 0.24 p = 0.047).
Why it matters
In 223 participants across the Alzheimer's continuum, associations between KLOTHO-VS heterozygosity and higher cerebrospinal fluid Aβ42 and Aβ42/40 ratio were non-significant overall, except when restricted to APOE ε4 carriers. This is observational biomarker research and does not show that KLOTHO-VS heterozygosity or α-Klotho protein treats or prevents Alzheimer's disease.
Study details
- Participants223
- Evidence strengthLow
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer s Disease) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 223 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Jakub Hort: h-index 55 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Arizona State University: institution h-index 987 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40112321) |
| Free to read | 2 / 2 | Free to read |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1177/13872877251326199
- PubMed: 40112321
- Original source →
- Free full text: Journal of Alzheimer s Disease →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Disease mechanisms from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.